Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 193 participants.
Also called NCT06416865
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 193 participants
- Sponsor
- AJU Pharm Co., Ltd.
- Registry
-
NCT06416865
-
- Other papers using this trial's data
- Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06416865. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-18 (actual); primary completion 2024-12-23 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
- Condition
- Essential Hypertension
- Intervention (Drug)
- AJU-C52L, AJU-C52
- Intervention (Drug)
- C52R1L, C52R1M
- Lead sponsor
- AJU Pharm Co., Ltd.
Record details
- Record id
cardio:ct-nct06416865- Content hash
b9a7d13ef6f379cf73999fa3da5a8278acac4412ff920a4941495e635dce5a7f